Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: Implications for experimental psychosis

Behavioural Brain Research

Volumn 216, Issue 1, 2011, Pages 247-254

  Chatterjee, Manavi ^a   Ganguly, Surajit ^b   Srivastava, Mukesh ^a   Palit, Gautam ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b Institute of Molecular Medicine   (India)

Author keywords

Forced swim test; Ketamine; Locomotor activity; Passive avoidance test; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; KETAMINE; RISPERIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; EXPERIMENTAL STUDY; FORCED SWIMMING TEST; HYPERACTIVITY; IMMOBILIZATION; LATENT PERIOD; LOCOMOTION; LONG TERM EXPOSURE; MALE; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PASSIVE AVOIDANCE; PRIORITY JOURNAL; PSYCHOSIS;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; CLOZAPINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HALOPERIDOL; KETAMINE; MALE; MICE; MOTOR ACTIVITY; PSYCHOTIC DISORDERS; RANDOM ALLOCATION; RISPERIDONE; SCHIZOPHRENIA; SUBSTANCE WITHDRAWAL SYNDROME; SWIMMING;

EID: 78149413364     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.08.001     Document Type: Article

References (41)

1. Alex K.D., Pehek E.A. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 2007, 113:296-320.
2. Anden N.E. Dopamine turnover in the corpus striatum and the lumbic system after treatment with neuroleptic and anti-acetylcholine drugs. J Pharm Pharmacol 1972, 24:905-906.
3. Bracs P.U., Gregory P., Jackson D.M. Passive avoidance in rats: disruption by dopamine applied to the nucleus accumbens. Psychopharmacology (Berl) 1984, 83:70-75.
4. Byrd L.D., Standish L.J., Howell L.L. Behavioral effects of phencyclidine and ketamine alone and in combination with other drugs. Eur J Pharmacol 1987, 144:331-341.
5. Carlsson A., Hansson L.O., Waters N., Carlsson M.L. Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci 1997, 61:75-94.
6. Carlsson A., Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3 methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 1963, 20:140-144.
7. Cohen M.G., Chan S.L., Bhargava H.N., Trevor A.J. Inhibition of mammalian brain acetylcholinesterase by ketamine. Biochem Pharmacol 1974, 23:1647-1652.
8. Das A., Kapoor K., Sayeepriyadarshini A., Dikshit M., Palit G., Nath C. Immobilization stress-induced changes in brain acetylcholinesterase activity and cognitive function in mice. Pharmacol Res 2000, 42:213-217.
9. Duncan G.E., Moy S.S., Knapp D.J., Mueller R.A., Breese G.R. Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Res 1998, 787:181-190.
10. Enomoto T., Noda Y., Nabeshima T. Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis. Methods Find Exp Clin Pharmacol 2007, 29:291-301.
11. Fernandez-Tome M.P., Sanchez-Blazquez P., del Rio J. Impairment by apomorphine of one-trial passive avoidance learning in mice: the opposing roles of the dopamine and noradrenaline systems. Psychopharmacology (Berl) 1979, 61:43-47.
12. Gao X.M., Hashimoto T., Tamminga C.A. Phencyclidine (PCP) and dizocilpine (MK801) exert time-dependent effects on the expression of immediate early genes in rat brain. Synapse 1998, 29:14-28.
13. Gass P., Herdegen T., Bravo R., Kiessling M. Induction and suppression of immediate early genes in specific rat brain regions by the non-competitive N-methyl-d-aspartate receptor antagonist MK-801. Neuroscience 1993, 53:749-758.
14. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the " right stuff" ?. Schizophr Bull 2000, 26:119-136.
15. Harvey P.D., Green M.F., Keefe R.S., Velligan D.I. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry 2004, 65:361-372.
16. Hayase T., Yamamoto Y., Yamamoto K. Behavioral effects of ketamine and toxic interactions with psychostimulants. BMC Neurosci 2006, 7:25.
17. Ichihara K., Nabeshima T., Kameyama T. Effects of haloperidol, sulpiride and SCH 23390 on passive avoidance learning in mice. Eur J Pharmacol 1988, 151:435-442.
18. Ichihara K., Nabeshima T., Kameyama T. Opposite effects induced by low and high doses of apomorphine on single-trial passive avoidance learning in mice. Pharmacol Biochem Behav 1988, 30:107-113.
19. Imre G., Fokkema D.S., Den Boer J.A., Ter Horst G.J. Dose-response characteristics of ketamine effect on locomotion, cognitive function and central neuronal activity. Brain Res Bull 2006, 69:338-345.
20. Irifune M., Shimizu T., Nomoto M. Ketamine-induced hyperlocomotion associated with alteration of presynaptic components of dopamine neurons in the nucleus accumbens of mice. Pharmacol Biochem Behav 1991, 40:399-407.
21. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991, 148:1301-1308.
22. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980, 20:379-382.
23. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994, 51:199-214.
24. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995, 13:9-19.
25. Lorrain D.S., Baccei C.S., Bristow L.J., Anderson J.J., Varney M.A. Effects of ketamine and N-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003, 117:697-706.
26. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997, 17:2921-2927.
27. Nakao S., Nagata A., Miyamoto E., Masuzawa M., Murayama T., Shingu K. Inhibitory effect of propofol on ketamine-induced c-Fos expression in the rat posterior cingulate and retrosplenial cortices is mediated by GABAA receptor activation. Acta Anaesthesiol Scand 2003, 47:284-290.
28. Narayan S., Kass K.E., Thomas E.A. Chronic haloperidol treatment results in a decrease in the expression of myelin/oligodendrocyte-related genes in the mouse brain. J Neurosci Res 2007, 85:757-765.
29. Noda Y., Mamiya T., Furukawa H., Nabeshima T. Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice. Eur J Pharmacol 1997, 324:135-140.
30. Noda Y., Yamada K., Furukawa H., Nabeshima T. Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Br J Pharmacol 1995, 116:2531-2537.
31. Nyback H., Sedvall G., Kopin I.J. Accelerated synthesis of dopamine-C14 from tyrosine-C14 in rat brain after chlorpromazine. Life Sci 1967, 6:2307-2312.
32. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995, 52:998-1007.
33. Oye I., Hustveit O., Moberg E., Pausen O., Skoglund L. The chiral forms of ketamine as probes for NMDA receptor function in humans. NMDA receptor related agents: biochemistry, pharmacology, and behavior 1991, 381-389. NPP Books, Ann Arbor, MI. T. Kameyama, T. Nabeshima, E. Domino (Eds.).
34. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977, 229:327-336.
35. Rasmussen T., Fink-Jensen A., Sauerberg P., Swedberg M.D., Thomsen C., Sheardown M., et al. The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance. Schizophr Res 2001, 49:193-201.
36. Reus V.I. Mental disorders. Harrison's principles of internal medicine 2008, 2710-2723. McGraw-Hill, New York. A.S. Fauci, E. Braunwald, D.L. Kasper, S.L. Hauser, D.L. Longo, J.L. Jameson, J. Loscalzo (Eds.).
37. Sams-Dodd F. Effects of continuous d-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology 1998, 19:18-25.
38. Sanberg P.R., Zoloty S.A., Willis R., Ticarich C.D., Rhoads K., Nagy R.P., et al. Digiscan activity: automated measurement of thigmotactic and stereotypic behavior in rats. Pharmacol Biochem Behav 1987, 27:569-572.
39. Saykin A.J., Gur R.C., Gur R.E., Mozley P.D., Mozley L.H., Resnick S.M., et al. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry 1991, 48:618-624.
40. Smith D.J., Azzaro A.J., Zaldivar S.B., Palmer S., Lee H.S. Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines. Neuropharmacology 1981, 20:391-396.
41. Smith D.J., Pekoe G.M., Martin L.L., Coalgate B. The interaction of ketamine with the opiate receptor. Life Sci 1980, 26:789-795.